A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer

被引：0

作者：

Sara M. Balch

Ines Vaz-Luis

Tianyu Li

Nabihah Tayob

Esha Jain

Karla Helvie

Jorge E. Buendia-Buendia

Erin Shannon

Steven J. Isakoff

Nadine M. Tung

Ian E. Krop

Nancy U. Lin

Nikhil Wagle

Rachel A. Freedman

机构：

[1] The Broad Institute of MIT and Harvard,Department of Data Sciences

[2] Department of Medical Oncology,undefined

[3] Dana-Farber Cancer Institute,undefined

[4] Institut Gustave Roussy,undefined

[5] Unit INSERM 981,undefined

[6] Dana-Farber Cancer Institute,undefined

[7] Massachusetts General Hospital,undefined

[8] Harvard Medical School,undefined

[9] Beth Israel Deaconess Medical Center,undefined

[10] Cellarity,undefined

[11] Inc.,undefined

来源：

Breast Cancer Research and Treatment | 2021年 / 189卷

关键词：

HER2+ breast cancer; Trastuzumab; Pertuzumab; Eribulin mesylate;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：411 / 423

页数：12

共 50 条

[31] Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer - A pilot phase II study [J].

Montemurro, F ;

Choa, G ;

Faggiuolo, R ;

Sperti, E ;

Capaldi, A ;

Donadio, M ;

Minischetti, M ;

Salomone, A ;

Vietti-Ramus, G ;

Alabiso, O ;

Aglietta, M .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (01) :95-97

[32] Efficacy of First-Line Treatment With Pertuzumab and Trastuzumab in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Routine Clinical Practice [J].

Camejo, Natalia ;

Castillo, Cecilia ;

Amarillo, Dahiana ;

de los Santos, Heber ;

Samurio, Gaston ;

Silva-Marquez, Ahinara ;

Sosa, Franco ;

Vera, Claudia ;

Xavier, Rocio ;

Herrera, Guadalupe ;

Alonso, Isabel ;

Krygier, Gabriel .

WORLD JOURNAL OF ONCOLOGY, 2024, 15 (03) :454-462

[33] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer [J].

N. U. Lin ;

D. S. Seah ;

R. Gelman ;

S. Desantis ;

E. L. Mayer ;

S. Isakoff ;

P. DiPiro ;

I. E. Krop ;

S. E. Come ;

D. Weckstein ;

E. P. Winer ;

H. J. Burstein .

Breast Cancer Research and Treatment, 2013, 139 :403-410

[34] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer [J].

Lin, N. U. ;

Seah, D. S. ;

Gelman, R. ;

Desantis, S. ;

Mayer, E. L. ;

Isakoff, S. ;

DiPiro, P. ;

Krop, I. E. ;

Come, S. E. ;

Weckstein, D. ;

Winer, E. P. ;

Burstein, H. J. .

BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (02) :403-410

[35] Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma [J].

Chung, Christine H. ;

Germain, Alexis ;

Subramaniam, Rathan M. ;

Heilmann, Andreas M. ;

Fedorchak, Kyle ;

Ali, Siraj M. ;

Miller, Vincent A. ;

Palermo, Robert A. ;

Fakhry, Carole .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2017, 39 (01) :E15-E19

[36] Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors [J].

Niikura, Naoki ;

Liu, Jun ;

Hayashi, Naoki ;

Mittendorf, Elizabeth A. ;

Gong, Yun ;

Palla, Shana L. ;

Tokuda, Yutaka ;

Gonzalez-Angulo, Ana M. ;

Hortobagyi, Gabriel N. ;

Ueno, Naoto T. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) :593-599

[37] Prolonged Responses With Trastuzumab Emtasine Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer Refractory to Trastuzumab and Pertuzumab: Systematic Review of Evidence [J].

Martin Huertas, Roberto ;

Fernandez Abad, Maria ;

Corral de la Fuente, Elena ;

Serrano Domingo, Juan Jose ;

Martinez Janez, Noelia .

CLINICAL BREAST CANCER, 2021, 21 (05) :391-398

[38] Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study [J].

Ozaki, Yukinori ;

Aoyama, Yosuke ;

Masuda, Jun ;

Inagaki, Lina ;

Kawai, Saori ;

Shibayama, Tomoko ;

Maeda, Tetsuyo ;

Kurata, Mami ;

Yoshida, Kazuyo ;

Saeki, Sumito ;

Hosonaga, Mari ;

Fukada, Ippei ;

Hara, Fumikata ;

Kobayashi, Takayuki ;

Kobayashi, Kokoro ;

Miyake, Satoshi ;

Takano, Toshimi ;

Ueno, Takayuki ;

Ohno, Shinji .

BMC CANCER, 2022, 22 (01)

[39] A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer [J].

Chia, Stephen K. ;

Ellard, Susan L. ;

Mates, Mihaela ;

Welch, Stephen ;

Mihalcioiu, Catalin ;

Miller, Wilson H., Jr. ;

Gelmon, Karen ;

Lohrisch, Caroline ;

Kumar, Vikaash ;

Taylor, Sara ;

Hagerman, Linda ;

Goodwin, Rachel ;

Wang, Tao ;

Sakashita, Shingo ;

Tsao, Ming S. ;

Eisenhauer, Elizabeth ;

Bradbury, Penelope .

BREAST CANCER RESEARCH, 2017, 19

[40] A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial) [J].

Takahashi, Kenta ;

Ishibashi, Eri ;

Kubo, Toshio ;

Harada, Yohei ;

Hayashi, Hideyuki ;

Kano, Masayuki ;

Shimizu, Yasushi ;

Shirota, Hidekazu ;

Mori, Yukiko ;

Muto, Manabu ;

Ishioka, Chikashi ;

Dosaka-Akita, Hirotoshi ;

Matsubara, Hisahiro ;

Nishihara, Hiroshi ;

Sueoka-Aragane, Naoko ;

Toyooka, Shinichi ;

Hirakawa, Akihiro ;

Tateishi, Ukihide ;

Miyake, Satoshi ;

Ikeda, Sadakatsu .

MEDICINE, 2020, 99 (32) :E21457

← 1 2 3 4 5 →